Should I Start Eliquis or Stay on Aspirin After a Blood Clot?

Eliquis (apixaban) and low-dose aspirin both thin the blood, but they are not interchangeable. Clinical trials show that continuing Eliquis after the first 6–12 months of treatment can cut recurrent clot risk to about 2 percent a year, whereas aspirin lowers the risk to about 6 percent. The trade-off is a slightly higher—but still low—rate of major bleeding with Eliquis. Most guidelines favor Eliquis (or another direct oral anticoagulant) for people at moderate-to-high risk of another clot; aspirin remains an option when bleeding risk or cost outweighs clot risk.

• Roughly 1 in 3 adults who stop all anticoagulation after an unprovoked clot will develop another clot within 5 years.
• The AMPLIFY-EXT study found apixaban 2.5 mg twice daily cut recurrent VTE to 1.7 % per year without an increase in major bleeding.
• Aspirin 81–100 mg daily reduced recurrent VTE to about 6 % per year in the WARFASA and ASPIRE trials.
• Eliquis is preferred for patients with prior pulmonary embolism, obesity, or active cancer—groups at highest risk for recurrence.
• Use Rx.com to compare prices—most patients pay about $200 or less for a 30-day Eliquis prescription with a free discount card.

What Eliquis and Aspirin Are—two very different anticoagulants

Eliquis is a prescription direct oral anticoagulant (DOAC) that blocks factor Xa, while aspirin is an over-the-counter antiplatelet that prevents platelets from sticking together. Both lower the risk of dangerous clots, but they do so at different points in the clotting cascade and therefore have different strengths and side-effect profiles. The U.S. Food and Drug Administration originally approved Eliquis in 2012 for stroke prevention in atrial fibrillation, then for treatment and secondary prevention of deep-vein thrombosis (DVT) and pulmonary embolism (PE). Low-dose, “baby” aspirin (81–100 mg) has been used off-label for secondary VTE prevention based on supportive trial data.

Definition: Venous thromboembolism (VTE) is a collective term for DVT—usually in the legs—and PE, a clot that travels to the lungs. After a first unprovoked VTE, life-time recurrence risk exceeds 30 percent.

Many patients with heart disease already take other cardioprotective medicines such as atorvastatin for cholesterol or lisinopril for blood pressure. These drugs do not replace the need for an anticoagulant but may influence overall bleeding risk.

How They Prevent New Clots—mechanisms and onset

Eliquis begins inhibiting factor Xa within 2–4 hours of the first dose, whereas aspirin’s platelet-blocking effect starts within 30 minutes but is less potent against venous clots. Factor Xa sits at a key junction in the coagulation cascade where clotting factors convert prothrombin to thrombin. By blocking it, Eliquis prevents the formation of the fibrin mesh that stabilizes clots. Aspirin, in contrast, irreversibly acetylates cyclooxygenase-1 in platelets, reducing thromboxane A₂ and thereby platelet aggregation.

Potency matters: Venous clots are rich in fibrin rather than platelets, so targeting factor Xa produces a larger relative risk reduction than targeting platelets alone. That difference explains the approximately four-fold stronger protection seen in head-to-head trials.

How Common Are Second Clots?—numbers your doctor looks at

Without any ongoing therapy, about 11 percent of people will have another clot within the first year and 30–35 percent within five years. Age over 60, male sex, obesity, and an unprovoked first event all push risk higher. In the placebo arm of the AMPLIFY-EXT trial, recurrent VTE occurred at an annualized rate of 11 percent, compared with 1.7 percent on low-dose apixaban. In the WARFASA trial, aspirin cut that number to roughly 6.6 percent per year.

More detailed numbers—plus how long therapy usually continues—are covered in our guide how long to stay on Eliquis after a blood clot.

Who Benefits Most From Eliquis—patient profiles

Guidelines recommend a DOAC such as Eliquis for almost anyone whose clot was “unprovoked” or related to chronic risk factors. Major groups include:

• Prior pulmonary embolism: PEs recur more often and are more dangerous than leg-only DVTs.
• Active cancer: Tumors and chemotherapy both raise clotting risk.
• Obesity (BMI > 30): Heavier patients have roughly double the recurrence risk.
• Known thrombophilia: Factor V Leiden, prothrombin gene mutations, or antiphospholipid syndrome.
• Smokers and patients with uncontrolled blood pressure—often treated with hydrochlorothiazide—also benefit from stronger prevention.

Safety Risks to Weigh—bleeding, interactions, and reversibility

Major bleeding with Eliquis runs 0.1–0.4 percent per year in extension studies—about the same as aspirin but involving more serious sites. Gastrointestinal bleeds dominate. An FDA-approved reversal agent (andexanet alfa) can neutralize factor Xa inhibition in emergencies, whereas aspirin’s effect lasts for the lifespan of affected platelets (7–10 days) and is reversed by transfusion.

Drug interactions: Strong inhibitors of both CYP3A4 and P-gp (e.g., ketoconazole) can double Eliquis levels; enzyme inducers (e.g., rifampin) cut levels in half. Over-the-counter NSAIDs such as ibuprofen add bleeding risk to both Eliquis and aspirin.

How Doctors Decide—evidence and guidelines

The 2021 CHEST guideline gives Eliquis (or another DOAC) a strong recommendation for extended therapy after an unprovoked VTE, while suggesting aspirin only when bleeding risk outweighs clot risk. Doctors weigh five main factors: clot provoking factors, bleeding history, kidney function, patient preference, and cost. If you are already using a statin such as atorvastatin, your care team will check for potential additive liver effects but typically proceeds with DOAC therapy.

Cost and Convenience—monthly price check

Sticker shock is real—Eliquis averages about $637 for a 30-day supply without insurance or coupons, versus under $5 for a month of generic low-dose aspirin. The gap narrows when you use a free discount card or an insurance copay card.

Tip: Use the free Rx.com discount card when you drop off your prescription—many pharmacies honor the lower price even if you have insurance.